WASHINGTON — The Biden administration has decided that most Americans should get a coronavirus booster vaccination eight months after they received their second shot, and could begin offering third shots as early as mid- to late September, according to administration officials familiar with the discussions.
Officials are planning to announce the administration’s decision as early as this week. Their goal is to let Americans who received the Pfizer-BioNTech or Moderna vaccines know now that they will need additional protection against the Delta variant that is causing caseloads to surge across the nation. The new policy will depend on the Food and Drug Administration’s authorization of additional shots.
Officials said they expect that recipients of the Johnson & Johnson vaccine, which was authorized as a one-dose regimen, will also require an additional dose. But they are waiting for the results of that firm’s two-dose clinical trial, expected later this month.
The first boosters are likely to go to nursing home residents and health care workers, followed by other older people who were near the front of the line when vaccinations began late last year. Officials envision giving people the same vaccine they originally received.
For weeks, Biden administration officials have been analyzing the rising trend in Covid-19 cases, trying to figure out if the Delta variant is better able to evade the vaccines than earlier versions of the virus, or if the vaccines were losing potency. According to some administration experts, both could be true, worsening a pandemic that the nation fervently hoped had been curbed.
Officials have been particularly concerned about data from Israel suggesting that the Pfizer-BioNTech vaccine’s protection against severe disease has fallen significantly for elderly people who got their second shot in January or February.
Some administration officials have viewed Israel as a kind of template for the United States because it started vaccinating its population sooner. Israel has almost exclusively used the Pfizer-BioNTech vaccine, and it has a nationalized health care system that allows it to systematically track patients.
The latest data from Israel, posted on the government’s website on Monday, shows what some experts describe as continued erosion of the efficacy of the Pfizer vaccine over time — both against mild or asymptomatic Covid-19 infections in general and against severe disease among the elderly.
“It shows a pretty steep decline and effectiveness against infection, but it’s still a bit murky about protection against severe disease,” said Dr. Peter J. Hotez, a vaccine expert at the Baylor College of Medicine in Houston, who reviewed the data posted by Israel at the request of The New York Times.